NASDAQ · Healthcare · Biotechnology
Kailera Therapeutics, Inc.
KLRA
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. CEO Ronald C. Renaud Jr. · Market cap $2.9B.
$22.39
+0.09 · +0.40%
52w hi $28.2352w lo $20.87
Off 52w high 20.4%
80
STRONG
Current InsiderScore
Corp · 90d
5
5 buys · 0 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
4
2 strong · 2 notable
Analyst consensus
—
—
Section 01
Recent Form 4 filings
5 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Apr 20 | BAIN CAPITAL INVESTORS LLC | Buy | 8,398,438 | $16.00 | +$134.38M | 80 | |
| Apr 20 | Bain Capital Life Sciences Investors, LLC | Buy | 1,562,500 | $16.00 | +$25.00M | 73 | |
| Apr 20 | Adam Koppel | Buy | 1,562,500 | $16.00 | +$25.00M | 73 | |
| Apr 20 | RTW INVESTMENTS, LP | Buy | 500,000 | $16.00 | +$8.00M | 55 | |
| Apr 20 | Andrew T. Kaplan | Buy | 8,398,438 | $16.00 | +$134.38M | 80 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
JunJulAugSepOctNovDecJanFebMarAprMay